Uwell Biopharma, Inc. (TPEX:7902)

Uwell Biopharma Statistics

Total Valuation

Uwell Biopharma has a market cap or net worth of TWD 8.95 billion. The enterprise value is 8.73 billion.

Market Cap	8.95B
Enterprise Value	8.73B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Uwell Biopharma has 200.00 million shares outstanding. The number of shares has increased by 105.26% in one year.

Current Share Class	200.00M
Shares Outstanding	200.00M
Shares Change (YoY)	+105.26%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19,888.89
PB Ratio	38.89
P/TBV Ratio	38.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-159.18
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-216.27

Financial Position

The company has a current ratio of 14.15, with a Debt / Equity ratio of 0.01.

Current Ratio	14.15
Quick Ratio	14.12
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.06
Interest Coverage	-333.99

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-24.09%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	70.50
Average Volume (20 Days)	1,406,019

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Uwell Biopharma had revenue of TWD 450,000 and -54.86 million in losses. Loss per share was -0.47.

Revenue	450,000
Gross Profit	301,000
Operating Income	-55.44M
Pretax Income	-54.86M
Net Income	-54.86M
EBITDA	-52.36M
EBIT	-55.44M
Loss Per Share	-0.47

Balance Sheet

The company has 220.31 million in cash and 2.57 million in debt, with a net cash position of 217.73 million or 1.09 per share.

Cash & Cash Equivalents	220.31M
Total Debt	2.57M
Net Cash	217.73M
Net Cash Per Share	1.09
Equity (Book Value)	230.13M
Book Value Per Share	1.97
Working Capital	205.18M

Cash Flow

In the last 12 months, operating cash flow was -39.91 million and capital expenditures -467,000, giving a free cash flow of -40.38 million.

Operating Cash Flow	-39.91M
Capital Expenditures	-467,000
Free Cash Flow	-40.38M
FCF Per Share	-0.20

Margins

Gross Margin	66.89%
Operating Margin	-12,320.44%
Pretax Margin	-12,190.89%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Uwell Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-105.26%
Shareholder Yield	-105.26%
Earnings Yield	-0.61%
FCF Yield	-0.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Uwell Biopharma has an Altman Z-Score of -0.26 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.26
Piotroski F-Score	2